Although neurological disorders are the leading cause of disability and the second cause of deaths worldwide, access to affordable drugs to treat neurological patients is appallingly low in most countries.

The Lancet Neurology published an article in December 2019 on the Multiple Sclerosis International Federation (MSIF)’s application to include three disease-modifying therapies for multiple sclerosis (glatiramer acetate, fingolimod, and ocrelizumab) submitted to the World Health Organization (WHO) Model list of Essential Medicines (EML).

Indeed, as the editorial stresses out, there is a pressing need to include more neurological treatments on the WHO EML. The Lancet also mentions that MPP’s access-oriented voluntary licensing strategy could help improve access to neurological treatments in resource-limited settings.

Read the full article